International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies.

Blood Adv · 2023 · PMC10628811 · PMID 37648672

Europe PMC DOI

hedged sentence

0.2000

closest p · 4.0× alpha

0.2000

boldest claim

The sentences

did not reach statistical significanceP = .2not close (p > 0.1)

Numerically, the first-line median TTNT appeared to favor patients with stage IVA1 over stage IVA2 (6.0 [95% CI, 5.0-7.6] vs 4.4 [95% CI, 3.6-6.9] months, respectively) but did not reach statistical significance ( P = .2).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.